Navigation Links
Caliper Life Sciences Reports First Quarter 2011 Results
Date:5/2/2011

ress with the integration of CRi, and overall positive momentum going into the second quarter.  We had strong revenue growth in each of our strategic business units as we continue to transform Caliper into a premier provider of tools, technologies and services enabling personalized medicine.  In addition, we were pleased to deliver higher gross margins and positive operating cash flow for our third consecutive quarter," commented Kevin Hrusovsky, President and CEO of Caliper Life Sciences.   "We remain encouraged regarding the strength of our end markets, namely next generation sequencing, molecular diagnostics, biologics, tissue analysis and imaging, and the momentum of our new products and services associated with personalizing medicine / healthcare," added Hrusovsky.

Analysis of First Quarter 2011 Results

  • Caliper's revenues increased 25% in the first quarter of 2011 compared to the same period of 2010.  Non-GAAP revenues grew 37% in the first quarter of 2011 compared to the same period of 2010, comprised of 26% organic growth, 10% acquisition-driven growth and 1% favorable currency benefit.
  • Revenues from Caliper's Imaging business unit grew 44%, comprised of 25% growth from existing pre-clinical in vivo molecular imaging product lines due to continuing strong market demand and 19% acquisition-driven growth added by CRi's tissue analysis products.
  • Revenues from Caliper's Research business unit grew 22% on a non-GAAP basis excluding the impact from certain Automation product lines divested in May 2010.  Revenue related to Caliper's LabChip products grew 30% driven by strong demand for research applications, next-generation sequencing and adoption for molecular diagnostic applications.  Revenue related to Caliper's ongoing Automation products grew 11% on a non-GAAP basis, driven by growing application needs for genomic sample preparation and next-generation sequencing.
  • Revenues from Caliper's C
    '/>"/>

  • SOURCE Caliper Life Sciences, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Caliper Life Sciences to Present at the 36th Annual Deutsche Bank Health Care Conference
    2. Caliper Life Sciences First Quarter Results Conference Call Notice
    3. Caliper Life Sciences Announces Date and Location of its 2011 Annual Meeting of Stockholders
    4. Caliper Life Sciences Launches Novel COX-2 Probe to Enable Personalized Medicine Research
    5. Caliper Life Sciences and HistoRx to Provide Integrated Solutions for Superior Protein Quantification of Biomarkers in Tissue
    6. Analysis of Calipers Phase I EPA ToxCast™ Data Published in Leading Scientific Journal
    7. Caliper and Covaris Establish Co-Marketing Agreement to Simplify Next Generation Sequencing
    8. Caliper Life Sciences Fourth Quarter and Fiscal Year 2010 Financial Results Conference Call Notice
    9. Caliper Life Sciences IVIS® Optical Imaging System Adoption Surpasses 1000 Units: Validated Drug Research, Discovery and Development Tool Enables Advances in Personalized Medicine
    10. Caliper Life Sciences Announces Availability of Automated TruSeq™ Next Generation Sequencing Protocols
    11. Caliper and Seegene Partner to Provide Innovative Multiplex Molecular Diagnostics Products
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/26/2014)... , Nov. 25, 2014  goBalto, Inc., the ... been recognized as a winner of Red Herring,s ... Global Top 100 North America award in 2013, marking ... technology landscape. Red Herring,s Top 100 Global ... promising new companies and entrepreneurs. Red Herring editors were ...
    (Date:11/26/2014)... 25, 2014   Heska Corporation (NASDAQ: ... a provider of advanced veterinary diagnostic and other specialty ... Executive Chair, will attend The Benchmark Company, LLC,s Micro Cap ... will be held at The Palmer House Hilton, 17 E. ... a.m. to 2:30 p.m. Please email hska@haydenir.com or ...
    (Date:11/26/2014)... and LONDON , Nov. 25, 2014 /PRNewswire/ ... AZN ) today announced that AMAGINE-2 TM , ... brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg ... were each shown to be superior to Stelara on the ...
    Breaking Medicine Technology:goBalto Selected as a 2014 Red Herring Top 100 Global Company 2goBalto Selected as a 2014 Red Herring Top 100 Global Company 3Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
    ... Safety and Efficacy Data Presented at 1st IASLC-ESMO European Lung ... ... 23 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company ... 2,clinical trial of picoplatin confirming previously announced interim,results showing a survival ...
    ... 23 Archus Orthopedics, Inc.,announced today that it ... TFAS-C(TM) system, the newest addition to the company,s ... which degenerative changes in,the facet joints result in ... legs. Traditionally, patients with moderate to,severe spinal stenosis ...
    Cached Medicine Technology:Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 2Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 3Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 4First Human Implant of New Archus Orthopedics Facet Replacement System 2
    (Date:11/27/2014)... News) -- Thanksgiving meals can pose a challenge for ... expert says. Many traditional Thanksgiving dishes -- such ... are gluten-free, but "when it comes to pies, stuffing, ... Dr. Anca Safta, director of the Gluten and Allergic ... in North Carolina, said in a center news release. ...
    (Date:11/27/2014)... Indian Trail, NC (PRWEB) November 27, 2014 ... for over 12 years in the Charlotte area ... and fraud examination services to businesses of varying ... with local business owners to meet all of ... received QuickBooks certification through the QuickBooks ProAdvisor Program. ...
    (Date:11/27/2014)... November 27, 2014 Two international trainers ... procedure will help one person with significant needs ... Saj Jivraj and Dr. Mamaly Reshad of the Anacapa ... have launched a website devoted to helping dentist learn ... the website would be devoted to helping a patient ...
    (Date:11/27/2014)... Washington, DC (PRWEB) November 27, 2014 “LAB.C” ... Report, which features the latest and coolest technology products available ... NewsWatch, conducted the product review and shared with ... cable for iOS and Android devices. , Consumers love portability ... LAB.C. Their Cable Case for the iPhone5 and 5S ...
    (Date:11/27/2014)... This is a professional and in ... an overview analysis, the report introduces Insulin basic ... industry overview, policy analysis, and news analysis, etc. ... information on policy, plans for Insulin Market product ... more. , This report also provides ...
    Breaking Medicine News(10 mins):Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:Jeffrey Carlini becomes Intuit Proadvisor and receives QuickBooks certification 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 3Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 5Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 3
    ... possibility of risk of cerebral palsy , , WEDNESDAY, Sept. ... of steroids in-utero had no additional growth or neurodevelopmental ... studies found. , However, one of the studies did ... the incidence of cerebral palsy. , "In our ...
    ... the expanded use of FluMist (influenza virus vaccine live, intranasal) ... now approved for active immunization for the prevention of disease ... to 49 years of age. 1 Only one manufacturer ... influenza vaccine for children under four years of age. , ...
    ... That Tout Nutrition and Health, WESTLAKE ... of nutrition,in every bite! Dole Packaged Foods, ... Nutritious(TM) Signature Blends-unique combinations of,all-natural frozen fruit ... selections enriched with antioxidants and,immunity health components, ...
    ... Force, Retaining Cataract Sales ... Force and Lowering Operating Costs, MONROVIA, Calif., ... reported progress in its deployment of a,direct U.S. sales force ... in the retention of key sales,representatives for its cataract products. ...
    ... A molecular recycling plant permits nerve cells in ... changeable enough to record new experiences, yet permanent ... discovery of this molecular recycling plant, detailed in a ... Neuron, provides new insights into how the basic units ...
    ... shrink the size of tumors, but some might ... population of cancer stem cells believed to drive ... Atlanta, Georgia at the American Association for Cancer ... in Cancer Therapeutic Development. , Our experiments suggest ...
    Cached Medicine News:Health News:Steroids Seem Safe for Babies at Risk of Early Birth 2Health News:Steroids Seem Safe for Babies at Risk of Early Birth 3Health News:Dole Invites Consumers to Show Their Wild Side! 2Health News:STAAR Surgical Reports Operational Progress 2Health News:STAAR Surgical Reports Operational Progress 3Health News:STAAR Surgical Reports Operational Progress 4Health News:New understanding of basic units of memory 2Health News:To evade chemotherapy, some cancer cells mimic stem cells 2
    Validated by decades of research and clinical experience, HFA is the accepted standard of care in glaucoma diagnosis and management. With HFA you can feel confident you're providing the best possible...
    ... Rapidlab 1200's speed and accuracy allow ... in a timely manner - something ... especially patients. In fact, the Rapidlab ... in just one minute. Its maintenance-free, ...
    ... challenges. One complete solution. , Increased requirements ... Staff turnover. These are just some of ... challenges that can impact the amount of ... , , You can't afford ...
    Dornier Holmium Laser for Urological Procedures...
    Medicine Products: